Posted on the October 31, 2017 under Promotions
ILLUMINA TRUSIGHT TUMOR 170
Get 10% off the NEW Illumina TruSight Tumor 170 kit!
OFFER ENDS: 20 DECEMBER 2017
A comprehensive next-generation sequencing assay that targets DNA and RNA variants from the same FFPE tumor sample. LEARN MORE >
|OP-101-1003||TruSight Tumor 170
Learn more >
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
Comprehensive Coverage of Cancer-Related Variants
Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
Accurate Results from Low-Quality Samples
Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
Integrated, Streamlined Workflow
DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.